<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="138013">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02066181</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2014-00264</org_study_id>
    <secondary_id>NCI-2014-00264</secondary_id>
    <secondary_id>A091105</secondary_id>
    <secondary_id>A091105</secondary_id>
    <secondary_id>U10CA031946</secondary_id>
    <nct_id>NCT02066181</nct_id>
  </id_info>
  <brief_title>Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis</brief_title>
  <official_title>A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase III trial compares the effects, good and/or bad, of sorafenib tosylate
      in treating patients with desmoid tumors or aggressive fibromatosis. Sorafenib tosylate may
      stop the growth of tumor cells by blocking some of the proteins needed for cell growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To compare the progression-free survival (PFS) rates of patients with desmoid tumors
      (DT)/deep fibromatosis (DF) who receive either sorafenib (sorafenib tosylate) or placebo
      using a double-blinded randomized phase III study.

      SECONDARY OBJECTIVES:

      I. To assess toxicity. II. To assess time to surgical intervention. III. To assess tumor
      response rates and survival.

      TERTIARY OBJECTIVES:

      I. To evaluate changes in magnetic resonance imaging (MRI) Tesla (T)2 to predict (or
      correlate) with a biological effect such as tumor growth (by Response Evaluation Criteria in
      Solid Tumors [RECIST] version [v]1.1), and pain palliation. (Correlative companion study)
      II. The mechanism of action of sorafenib in DT/DF remains unknown. In patients consenting to
      undergo the paired tumor biopsies (A091105-ST1), treatment induced changes will be
      quantified by histology, gene expression profiling, proteomic changes and selected
      interrogation of key pathways by Western blot and reverse transcription-polymerase chain
      reaction (RT-PCR). (Correlative companion study) III. To collect archival tissue, baseline
      (tumor, blood) and day 8 (tumor, blood) specimens for basic science research (A091105-ST1).
      (Correlative companion study) IV. To assess patient-reported adverse events and quality of
      life (QOL) as measured by the Patient-Reported Outcomes version of the Common Terminology
      Criteria for Adverse Events (PRO-CTCAE) and the single-item overall Linear Analogue
      Self-Assessment (LASA) (A091105-HO1). (Correlative companion study) V. To assess pain
      palliation measured by the &quot;worst pain&quot; item of the Brief Pain Inventory Short Form
      (A091105-HO1). (Correlative companion study)

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive sorafenib tosylate orally (PO) once daily (QD) on days 1-28.

      ARM II: Patients receive placebo PO QD on days 1-28. Patients may crossover to Arm I upon
      disease progression.

      In both arms, courses repeat every 28 days in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed up annually for up to 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>Time from randomization to the first occurrence of progression or death due to any cause, assessed up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Data following cross over will be analyzed and summarized separately from the data from the main course of treatment for these patients. Intention to treat principles will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, using the PRO-CTCAE v4.0</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Frequency tables, summary statistics, and categorical analysis will be used to compare the distributions of toxicity for patients treated with sorafenib tosylate vs placebo. Data for patients who have crossed over or having received surgical or radiotherapy intervention will be summarized independently from their primary course of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to surgical intervention during treatment</measure>
    <time_frame>Time between randomization to the patient undergoing therapeutic surgical resection for this disease, assessed up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>A log rank test will be used to compare the distributions of time to surgical intervention between the two arms using a 2-sided test and alpha=0.05 level of significance. Kaplan-Meier methodology will be used to estimate various time points and 95% confidence intervals will be calculated for these estimates. Surgery will be classified by outcome (eg, complete-macroscopic, complete-microscopic, or partial), type, location (eg, limb), thereafter analyzed by categorical analysis and descriptive statistics. Non-parametric methods will be used, as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Time between the date of randomization to until death, assessed up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Kaplan-Meier methodology and log rank tests will be used to compare OS between the groups at various time points (eg, 1 year rate, 2 year rate, etc) and 95% confidence intervals will be calculated for these estimates. Data following crossover will be analyzed and summarized separately from the main course of treatment for these patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best objective status between the two treatment arms according to RECIST v1.1</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compared between the two treatment arms and using the Cochran-Mantel-Haenszel test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Time between first tumor response and progression, assessed up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Kaplan Meier methodology will be used to estimate the distribution of duration of response and the log-rank test will be used to test for a difference in duration of response between the two arms.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percent change in tumor size by RECIST v1.1 (Correlative Companion Study-Imaging study)</measure>
    <time_frame>Baseline up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Best RECIST response (ordinal variable) will be correlated by Spearman's rho.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent changes in MRI T2 signal (Correlative Companion Study-Imaging study)</measure>
    <time_frame>Baseline up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent T2 signal change (continuous) will be correlated by Spearman's rho. The percent changes in MRI T2 signal from Week 8 to subsequent imaging will be compared between groups with &gt; 30% pain palliation using t-test or a nonparametric alternative (e.g., Wilcoxon rank-sum test).</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to pain progression measured by the &quot;worst pain&quot; item of the Brief Pain Inventory Short Form (Correlative Companion Study- A091105-H01 QOL study)</measure>
    <time_frame>Date of randomization to the earliest date that pain progression is observed, assessed up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as a &gt;= 30% increase compared with baseline in the worst pain intensity score (BPI-SF &quot;worst pain&quot; item) or either a &gt;= 30% increase in the average daily use of any type of opioid narcotic or the addition of a new opioid narcotic compared with baseline. Estimated for each arm using Kaplan-Meier estimates and will be compared between arms using a log- rank test. Descriptive statistics will include means, standard deviations, medians, and ranges for each continuous or ordinal scale/subscale/item by group at each time point.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to pain palliation measured by the &quot;worst pain&quot; item of the Brief Pain Inventory Short Form (Correlative Companion Study-A091105-H01 QOL study)</measure>
    <time_frame>Date of randomization to the earliest date that confirmed pain palliation is observed, assessed up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined at each time point as &gt;= 30% decrease from baseline in the worst pain intensity score (BPI-SF &quot;worst pain&quot; item), with neither a concomitant &gt;= 30% increase in average daily use of any opioid narcotic, nor addition of any new opioid narcotic, relative to baseline. Estimated for each arm using Kaplan-Meier estimates and will be compared between arms using a log- rank test. Descriptive statistics will include means, standard deviations, medians, and ranges for each continuous or ordinal scale/subscale/item by group at each time point.</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of pain palliation measured by the &quot;worst pain&quot; item of the Brief Pain Inventory Short Form (Correlative Companion Study- A091105-H01 QOL study)</measure>
    <time_frame>Time from the earliest date that confirmed pain palliation is observed to the earliest date that pain progression is observed, assessed up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined for all patients who experience confirmed pain palliation. Descriptive statistics will include means, standard deviations, medians, and ranges for each continuous or ordinal scale/subscale/item by group at each time point. Descriptive graphical techniques will include mean plots by group for each continuous or ordinal scale/subscale/item. Relative frequencies of responses for each ordinal item will also be generated at each time point by group.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of pain palliation measured by the &quot;worst pain&quot; item of the Brief Pain Inventory Short Form (Correlative Companion Study-A091105-H01 QOL study)</measure>
    <time_frame>Baseline up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rate of pain palliation at week 8 confirmed as week 12 will be compared between arms using a two-sided alpha=0.05 chi-squared tests at the time of the final analysis. Descriptive statistics will include means, standard deviations, medians, and ranges for each continuous or ordinal scale/subscale/item by group at each time point. Descriptive graphical techniques will include mean plots by group for each continuous or ordinal scale/subscale/item. Relative frequencies of responses for each ordinal item will also be generated at each time point by group.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cadherin-associated protein, beta 1 (CTNNB1) genotype (Correlative Companion Study-A091105-ST1 study)</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Associations among the possible predictors of response to sorafenib and CTNNBI mutations will be examined using Fisher's exact test, Kruskal-Wallis test, or Spearman's correlation coefficient as appropriate. Strata will be compared by using the log-rank test. Multivariate models will be constructed by introducing all variables aforementioned simultaneously into the model and then eliminating variables using the backward selection method. P values will be two-tailed and considered significant at alpha 0.05.</description>
  </other_outcome>
  <other_outcome>
    <measure>False discovery rate (FDR) (Correlative Companion Study- A091105-ST1 study)</measure>
    <time_frame>Up to day 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Permutation testing of the same selection will be performed 1000 times and the sample group labels switched around in each permutation. A two-sided t-test will be used to identify differentially expressed genes on log transformed data and those with a twofold change. False discovery rate (FDR) will be assessed by permutation testing (n = 1000) of the sample group labels. Enrichment will be assessed by one-sided Fisher's exact test with estimated FDR.</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment-specific gene expression signature  (Correlative Companion Study- A091105-ST1 study)</measure>
    <time_frame>Up to day 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>The analysis will identify over- and under-expressed genes in pre-treatment and day 8 biopsies as compared to all control samples.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in immunohistochemistry (IHC) score of vascular endothelial growth factor (VEGF) (Correlative Companion Study- A091105-ST1 study)</measure>
    <time_frame>Baseline up to day 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compared by paired t-test. Quantitative changes will be correlated with disease status at 1 year by Fishers exact test.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in IHC score of platelet-derived growth factor receptor (PDGFR) (Correlative Companion Study- A091105-ST1 study)</measure>
    <time_frame>Baseline up to day 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compared by paired t-test. Quantitative changes will be correlated with disease status at 1 year by Fishers exact test.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in IHC score of beta-catenin cytoplasm/nuclear ratio (Correlative Companion Study- A091105-ST1 study)</measure>
    <time_frame>Baseline up to day 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compared by paired t-test. Quantitative changes will be correlated with disease status at 1 year by Fishers exact test.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">83</enrollment>
  <condition>Desmoid Tumor</condition>
  <arm_group>
    <arm_group_label>Arm I (sorafenib tosylate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sorafenib tosylate PO QD on days 1-28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo PO QD on days 1-28. Patients may crossover to Arm I upon disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (sorafenib tosylate)</arm_group_label>
    <other_name>BAY 43-9006</other_name>
    <other_name>BAY 43-9006 Tosylate Salt</other_name>
    <other_name>BAY 54-9085</other_name>
    <other_name>Nexavar</other_name>
    <other_name>SFN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Optional correlative studies</description>
    <arm_group_label>Arm I (sorafenib tosylate)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Optional ancillary studies</description>
    <arm_group_label>Arm I (sorafenib tosylate)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have confirmation of DT/DF by local pathologist prior to registration

          -  Patients may have been treated with locoregional therapies such as major surgery,
             radiation, radiofrequency ablation, or cryosurgery provided this has been completed
             at least 4 weeks prior to registration and recovered from therapy related toxicity to
             less than CTCAE grade 2

          -  Patients may have been treated with cytotoxic, biologic (antibody), immune or
             experimental therapy, tyrosine kinase inhibitors, hormone inhibitors or nonsteroidal
             antiinflammatory drugs (NSAIDs) provided this has been completed at least 4 weeks
             prior to registration (6 weeks for mitomycin and nitrosoureas) and recovered from any
             therapy related toxicity to less than CTCAE grade 2

          -  Patients with prior or current treatment of sorafenib are excluded

          -  No concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin
             or warfarin-related agents, heparin, thrombin or Factor Xa inhibitors, or
             antiplatelet agents (e.g., clopidogrel); low dose aspirin (=&lt; 81 mg/day), low-dose
             warfarin (=&lt; 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are
             permitted; please note that drugs that strongly induce or inhibit cytochrome P450,
             family 3, subfamily A, polypeptide 4 (CYP3A4) or are associated with a risk of
             Torsades are not allowed; chronic concomitant treatment of CYP3A4 inducers is not
             allowed (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin,
             rifapentin, phenobarbital, and St. John's Wort); as part of the enrollment/informed
             consent procedures, the patient will be counseled on the risk of interactions with
             other agents, and what to do if new medications need to be prescribed or if the
             patient is considering a new over-the-counter medicine or herbal product; the
             following drugs are strong inhibitors of CYP3A4 and are not allowed during the
             treatment with sorafenib:

               -  Boceprevir

               -  Indinavir

               -  Nelfinavir

               -  Lopinavir/ritonavir

               -  Saquinavir

               -  Telaprevir

               -  Ritonavir

               -  Clarithromycin

               -  Conivaptan

               -  Itraconazole

               -  Ketoconazole

               -  Mibefradil

               -  Nefazodone

               -  Posaconazole

               -  Voriconazole

               -  Telithromycin

                    -  Drugs with possible or conditional risk of torsades should be used with
                       caution knowing that sorafenib could prolong the QT interval

          -  Patients must have measurable disease

          -  Patients have to meet one of the following criteria to be eligible:

               -  Disease determined unresectable or entailing unacceptably morbid surgery based
                  on 1 or more of the following characteristics:

                    -  Multifocal disease

                    -  Disease in which there is involvement or inadequate plane from:
                       neurovascular bundle, bone, skin, or viscera

                    -  Large size in relationship to location OR multi-compartment involvement

               -  Progression by radiographic imaging (10% increase in size by RECIST v1.1 within
                  6 months of registration)

               -  Patients with symptomatic disease which meets the following criteria Brief Pain
                  Inventory (BPI) score greater than or equal to 3 AND one of the following:

                    -  Inability to control pain with NSAIDs and considering addition of narcotics
                       OR

                    -  &gt; 30% increase in current use of narcotics OR

                    -  Addition of a new opioid narcotic

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2

          -  Patients who are pregnant or nursing are not eligible

          -  No patients with a history of cardiac disease: congestive heart failure &gt; class II
             New York Heart Association (NYHA); active coronary artery disease (CAD) (myocardial
             infarction or unstable angina within 6 months prior to study entry)

          -  No patients with inadequately controlled hypertension (defined as a blood pressure of
             &gt;= 150 mmHg systolic and/or &gt;= 90 mmHg diastolic), or any prior history of
             hypertensive crisis or hypertensive encephalopathy

          -  No patients with clinically significant gastrointestinal (GI) bleeding or bleeding
             diathesis within 30 days prior to registration

          -  Absolute neutrophil count &gt;= 1,500/mm^3

          -  Hemoglobin &gt;= 8 g/dl

          -  Platelets = 75,000/mm^3

          -  Total bilirubin =&lt; 1.5 x upper limits of normal (ULN)

          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase
             [AST])/serum glutamate pyruvate transaminase (SGPT) (aspartate aminotransferase
             [ALT]) =&lt; 1.5 X ULN

          -  Calculated creatinine clearance &gt;= 50 mL/min using the Cockcroft-Gault equation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mrinal Gounder</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer and Leukemia Group B</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>John B Amos Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew W. Pippas</last_name>
      <phone>706-660-6404</phone>
    </contact>
    <investigator>
      <last_name>Andrew W. Pippas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Regional Health Center</name>
      <address>
        <city>Mount Vernon</city>
        <state>Illinois</state>
        <zip>62864</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reid Hospital and Health Care Services</name>
      <address>
        <city>Richmond</city>
        <state>Indiana</state>
        <zip>47374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard M. Gross</last_name>
      <phone>765-983-3000</phone>
    </contact>
    <investigator>
      <last_name>Howard M. Gross</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care Incorporated</name>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard M. Gross</last_name>
      <phone>765-983-3000</phone>
    </contact>
    <investigator>
      <last_name>Howard M. Gross</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Care Cancer Center-Carrie J Babb Cancer Center</name>
      <address>
        <city>Bolivar</city>
        <state>Missouri</state>
        <zip>65613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CoxHealth Cancer Center</name>
      <address>
        <city>Branson</city>
        <state>Missouri</state>
        <zip>65616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Freeman Health System</name>
      <address>
        <city>Joplin</city>
        <state>Missouri</state>
        <zip>64804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital-Joplin</name>
      <address>
        <city>Joplin</city>
        <state>Missouri</state>
        <zip>64804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Phelps County Regional Medical Center</name>
      <address>
        <city>Rolla</city>
        <state>Missouri</state>
        <zip>65401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John's Clinic-Rolla-Cancer and Hematology</name>
      <address>
        <city>Rolla</city>
        <state>Missouri</state>
        <zip>65401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish West County Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian A. Van Tine</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Brian A. Van Tine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center-South County</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian A. Van Tine</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Brian A. Van Tine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John's Mercy Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Louis Cancer and Breast Institute-South City</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian A. Van Tine</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Brian A. Van Tine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center - Saint Peters</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian A. Van Tine</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Brian A. Van Tine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Springfield</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CoxHealth South Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Research Center</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gamini S. Soori</last_name>
      <phone>402-280-4100</phone>
    </contact>
    <investigator>
      <last_name>Gamini S. Soori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alegent Health Immanuel Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gamini S. Soori</last_name>
      <phone>402-280-4100</phone>
    </contact>
    <investigator>
      <last_name>Gamini S. Soori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alegent Health Lakeside Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gamini S. Soori</last_name>
      <phone>402-280-4100</phone>
    </contact>
    <investigator>
      <last_name>Gamini S. Soori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Creighton University Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gamini S. Soori</last_name>
      <phone>402-280-4100</phone>
    </contact>
    <investigator>
      <last_name>Gamini S. Soori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alegent Health Bergan Mercy Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gamini S. Soori</last_name>
      <phone>402-280-4100</phone>
    </contact>
    <investigator>
      <last_name>Gamini S. Soori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Missouri Valley Cancer Consortium CCOP</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gamini S. Soori</last_name>
      <phone>402-280-4100</phone>
    </contact>
    <investigator>
      <last_name>Gamini S. Soori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary K. Schwartz</last_name>
      <phone>212-305-8615</phone>
    </contact>
    <investigator>
      <last_name>Gary K. Schwartz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mrinal M. Gounder</last_name>
      <phone>212-639-7202</phone>
    </contact>
    <investigator>
      <last_name>Mrinal M. Gounder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care Inc - Western Hills</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45248</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard M. Gross</last_name>
      <phone>765-983-3000</phone>
    </contact>
    <investigator>
      <last_name>Howard M. Gross</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care Inc - Anderson</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard M. Gross</last_name>
      <phone>765-983-3000</phone>
    </contact>
    <investigator>
      <last_name>Howard M. Gross</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care Inc - Kenwood</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard M. Gross</last_name>
      <phone>765-983-3000</phone>
    </contact>
    <investigator>
      <last_name>Howard M. Gross</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Care Incorporated</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard M. Gross</last_name>
      <phone>765-983-3000</phone>
    </contact>
    <investigator>
      <last_name>Howard M. Gross</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Care Inc - Blue Ash</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard M. Gross</last_name>
      <phone>765-983-3000</phone>
    </contact>
    <investigator>
      <last_name>Howard M. Gross</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Valley Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard M. Gross</last_name>
      <phone>765-983-3000</phone>
    </contact>
    <investigator>
      <last_name>Howard M. Gross</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital - Dayton</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard M. Gross</last_name>
      <phone>765-983-3000</phone>
    </contact>
    <investigator>
      <last_name>Howard M. Gross</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dayton CCOP</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45420</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard M. Gross</last_name>
      <phone>765-983-3000</phone>
    </contact>
    <investigator>
      <last_name>Howard M. Gross</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samaritan North Health Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard M. Gross</last_name>
      <phone>765-983-3000</phone>
    </contact>
    <investigator>
      <last_name>Howard M. Gross</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care Inc</name>
      <address>
        <city>Fairfield</city>
        <state>Ohio</state>
        <zip>45014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard M. Gross</last_name>
      <phone>765-983-3000</phone>
    </contact>
    <investigator>
      <last_name>Howard M. Gross</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blanchard Valley Hospital</name>
      <address>
        <city>Findlay</city>
        <state>Ohio</state>
        <zip>45840</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard M. Gross</last_name>
      <phone>765-983-3000</phone>
    </contact>
    <investigator>
      <last_name>Howard M. Gross</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atrium Medical Center-Middletown Regional Hospital</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <zip>45005-1066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard M. Gross</last_name>
      <phone>765-983-3000</phone>
    </contact>
    <investigator>
      <last_name>Howard M. Gross</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne Hospital</name>
      <address>
        <city>Greenville</city>
        <state>Ohio</state>
        <zip>45331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard M. Gross</last_name>
      <phone>765-983-3000</phone>
    </contact>
    <investigator>
      <last_name>Howard M. Gross</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kettering Medical Center</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard M. Gross</last_name>
      <phone>765-983-3000</phone>
    </contact>
    <investigator>
      <last_name>Howard M. Gross</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Upper Valley Medical Center</name>
      <address>
        <city>Troy</city>
        <state>Ohio</state>
        <zip>45373</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard M. Gross</last_name>
      <phone>765-983-3000</phone>
    </contact>
    <investigator>
      <last_name>Howard M. Gross</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamad Cherry</last_name>
      <phone>405-271-4272</phone>
      <email>julie-traylor@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Mohamad Cherry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sujana Movva</last_name>
      <phone>215-728-4790</phone>
    </contact>
    <investigator>
      <last_name>Sujana Movva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute/University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer A. Wright</last_name>
      <phone>801-581-4477</phone>
      <email>clinical.trials@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer A. Wright</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital Of Martinsville</name>
      <address>
        <city>Martinsville</city>
        <state>Virginia</state>
        <zip>24115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sreedhar Katragadda</last_name>
      <phone>276-666-7827</phone>
    </contact>
    <investigator>
      <last_name>Sreedhar Katragadda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>February 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibroma</mesh_term>
    <mesh_term>Fibromatosis, Aggressive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
